6533b86efe1ef96bd12cb4fc

RESEARCH PRODUCT

E-beam crosslinked nanogels conjugated with monoclonal antibodies in targeting strategies

Natascia GrimaldiGiulio GhersiGiorgia AdamoMarta WaloMaria Antonietta SabatinoClelia Dispenza

subject

0301 basic medicinemedicine.drug_classConfocalmedia_common.quotation_subjecthigh-energy irradiationClinical BiochemistryNG[object Object]02 engineering and technologyMonoclonal antibodyBiochemistryCell LineFlow cytometrylaw.invention03 medical and health sciencesConfocal microscopylawFluorescence microscopemedicineHumansInternalizationMolecular Biologymedia_commonradiation-engineeredDrug Carriersmedicine.diagnostic_testChemistrywound healing assay.antiβ3 integrin antibodyAntibodies MonoclonalPovidoneactive-targetingBiological Transport021001 nanoscience & nanotechnologyMolecular biologyNanostructures030104 developmental biologyTargeted drug deliverynanogelpoly(N-vinyl pyrrolidone)Biophysics0210 nano-technologyGelswound healing assayNanogel

description

Abstract Poly(N-vinyl pyrrolidone)-based-nanogels (NGs), produced by e-beam irradiation, are conjugated with monoclonal antibodies (mAb) for active targeting purposes. The uptake of immuno-functionalized nanogels is tested in an endothelial cell line, ECV304, using confocal and epifluorescence microscopy. Intracellular localization studies reveal a faster uptake of the immuno-nanogel conjugate with respect to the ‘bare’ nanogel. The specific internalization pathway of these immuno-nanogels is clarified by selective endocytosis inhibition experiments, flow cytometry and confocal microscopy. Active targeting ability is also verified by conjugating a monoclonal antibody which recognizes the αvβ3 integrin on activated endothelial cells. Epifluorescence images of the ‘wound healing assay’ on ECV304 cells provide evidence of nanogels localization only in the target cells. Therefore, the immuno-nanogels produced have the potential to recognize specific cell types in heterogeneous systems, which makes them promising candidates for targeted drug delivery applications.

https://doi.org/10.1515/hsz-2016-0255